zadnja posodobitev :
19/11/2024
rak drog   Daunorubicin hydrochloride  
Brizgalka
Stabilnost raztopine Stabilnost mešanice Faktorji, ki vplivajo na stabilnost Kompatibilnost način aplikacije Viri pdf
   Kemična formula  

Lastniško ime   Lastniško ime     

Sestava pomožnih snovi je med paralelami lahko različna

Cerubidin Danska, Irska, Norveška, Švedska, Velika Britanija
Cerubidine Belgija, Čile, Francija, Kanada, Luksemburg, Maroko, Nizozemska, Švica, Tunizija, Turčija, Združene države Amerike
D Blastin Maroko
Daunac Kolumbija
Daunobin Indija
Daunoblastin Avstrija, Nemčija
Daunoblastina Grčija, Iran, Italija, Madžarska, Savdska Arabija, Španija, Venezuela
Daunocin Indija, Malezija, Peru
Daunogobbi Argentina
Daunomed Indija, Peru
Daunomycin Indija
Daunoplus Indija
Daunorubicin Avstralija, Kanada, nova Zelandija, Velika Britanija, Združene države Amerike
Daunorubicina Čile, Ekvador, Kolumbija, Mehika, Peru
Daunorubitec Indija
Daunoside Indija
Daunotec Indija, Venezuela
Daurocina Čile
Epodoxo Peru
Maxidauno Argentina, Ekvador
Oncodaunotec Kolumbija
Rubilem Mehika
Runabicon Kolumbija, Mehika
Zuleb Mehika
Viri   Brizgalka   Viri : Daunorubicin hydrochloride  
Tip objava
3 časopis Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81 časopis Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 časopis Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 časopis Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
148 časopis Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I.
Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.
Pharm Weekbl [Sci] 1992 ; 14: 365-369.
150 časopis Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
152 časopis Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J.
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion.
Pharm Acta Helv 1995 ; 70: 141-148.
169 časopis Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
244 časopis Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 časopis Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307 časopis Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 časopis Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
492 časopis Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
632 časopis Beijnen JH, Rosing H, De Vries PA, Underberg WJM.
Stability of anthracycline antitumour agents in infusion fluids.
J Parenter Sci Technol 1985 ; 39: 220-222.
643 časopis Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR.
In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide.
Cancer Treat Rep 1987 ; 71: 1189-1192.
686 časopis Wood MJ, Irwin WJ, Scott DK.
Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags.
J Clin Pharm Ther 1990 ; 15: 279-289.
905 časopis Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1265 časopis Wood MJ, Irwin WJ, Scott DK.
Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography.
J Clin Pharm Ther 1990 ; 15: 291-300.
1284 časopis Williams BA, Tritton TR.
Photoinactivation of anthracyclines.
Photochem Photobiol 1981 ; 34: 131-134.
1410 časopis Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 časopis Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1520 Traduction Laboratorij Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1625 časopis Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1897 časopis Sautou-Miranda V, Brigas F, Thibault M, Chopineau J.
Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage.
EJHP 2001 ; 7, 3: 108-115.
1982 časopis Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247 časopis Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3438 časopis Respaud R, Quenum L, Plichon C, Tournamille J.F, Gyan E, Antier D, Viaud-Massuard M.C.
A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids.
J Pharm Biomed Anal 2013 ; 83 : 164-170.
3474 Traduction Laboratorij Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3540 Traduction Laboratorij Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3604 Traduction Laboratorij Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012
3668 Traduction Laboratorij Dexamethasone - Summary of Product Characteristics
Hospira 2015

  Mentions Légales